The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against Cryptosporidium parvum

Parasitology

Volumn 138, Issue 11, 2011, Pages 1384-1391

  Bondioli, L ^a   Ludovisi, A ^b   Tosi, G ^a   Ruozi, B ^a   Forni, F ^a   Pozio, E ^b   Vandelli, M A ^a   Gomez Morales M A ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cryptosporidium parvum; Flow cytometry; Indinavir; Nanoparticles; Protease inhibitors

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INDINAVIR; NANOPARTICLE; TETRAMETHYLRHODAMINE;

ARTICLE; CELL CULTURE; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; IN VITRO STUDY; NEPHROTOXICITY; NONHUMAN; OOCYST; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; ANTIBODIES, PROTOZOAN; BIOCOMPATIBLE MATERIALS; CATTLE; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DRUG CARRIERS; DRUG COMPOUNDING; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOCONJUGATES; INDINAVIR; LACTIC ACID; MICROSCOPY, FLUORESCENCE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; POLYGLYCOLIC ACID; RHODAMINES; SPECTRUM ANALYSIS;

CRYPTOSPORIDIUM; CRYPTOSPORIDIUM PARVUM; CRYPTOSPORIDIUM SP.;

EID: 80053074197     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182011001119     Document Type: Article

References (49)

1. Amadi, B., Mwiya, S., Sianongo, S., Payne, L., Watuka, A., Katubulushi, M. and Kelly, P. (2009). High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMCInfectious Diseases 2, 195.
2. Askin, D. (1998). The synthesis of indinavir and other clinically useful HIV-1 protease inhibitors. Current Opinion in Drug Discovery & Development 1, 338-348.
3. Battegay, M., Fehr, J., Flückiger, U. and Elzi, L. (2008). Antiretroviral therapy of late presenters with advanced HIV disease. Journal of Antimicrobial Chemotherapy 62, 41-44. (Pubitemid 351865872)
4. Batycky, R. P., Hanes, J., Langer, R. and Edwards, D. A. (1997). A theoretical model of erosion and macromolecular release from biodegrading microspheres. Journal of Pharmaceutical Science 86, 1464-1477. (Pubitemid 28018331)
5. Bobin, S., Bouhouere, D., Dumpt, S., Boibieux, A., Grault, V. and Peyrnamond, D. (1998). Importance of antiprotease in the treatment of microsporidia and/or cryptosporidia infections in HIV-sero positive patients. Pathologie-Biologie 46, 418-419.
6. Cacciò, S., Pinter, E., Fantini, R., Mezzaroma, I. and Pozio, E. (2002). Human infection with Cryptosporidium felis: case report and literature review. Emerging Infectious Diseases 8, 85-86. (Pubitemid 34094289)
7. Cho, K., Wang, X., Nie, S., Chen, Z. and Shin, D. M. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research 14, 1310-1316. (Pubitemid 351413909)
8. Cohen, S., Yoshioka, T., Lucarelli, M., Huang, L. H. and Langer, R. (1991). Controlled delivery systems for proteins based on poly (lactic/ glycolic acid) microspheres. Pharmaceutical Research 8, 713-720.
9. Costantino, L., Gandolfi, F., Bossy-Nobs, L., Tosi, G., Gurny, R., Rivasi, F., Vandelli, M. A. and Forni, F. (2006). Nanoparticulate drug carriers based on hybrid poly(d,l-lactide-co-glycolide)-dendron structures. Biomaterials 27, 4635-4645. (Pubitemid 43783224)
10. Dimitrov, D. S., Feng, Y. and Prabakaran, P. (2008). Antibody-guided nanoparticles. Journal of Computational and Theoretical Nanoscience 5, 751-759.
11. Dou, H., Destache, C. J., Morehead, J. R., Mosley, R. L., Boska, M. D., Kingsley, J., Gorantla, S., Poluektova, L., Nelson, J. A., Chaubal, M., Werling, J., Kipp, J., Rabinow, B. E. and Gendelman, H. E. (2006). Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108, 2827-2835.
12. Ethelberg, S., Lisby, M., Vestergaard, L. S., Enemark, H. L., Olsen, K. E., Stensvold, C. R., Nielsen, H. V., Porsbo, L. J., Plesner, A.M. and Mølbak, K. (2009). A foodborne outbreak of Cryptosporidium hominis infection. Epidemiology and Infection 137, 348-356.
13. Fessi, H., Puisieux, F., Devissaguet, J. P., Ammoury, N. and Benita, S. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. International Journal of Pharmaceutics 55, R1-R4. (Pubitemid 19247505)
14. Gagné, J. F., Désormeaux, A., Perron, S., Tremblay, M. J. and Bergeron, M. G. (2002). Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochimica et Biophysica Acta 1558, 198-210. (Pubitemid 34081181)
15. Gargala, G. (2008). Drug treatment and novel drug target against Cryptosporidium. Parasite 15, 275-281.
16. Gref, R., Couvreur, P., Barratt, G. and Mysiakine, E. (2003). Surfaceengineered nanoparticles for multiple ligand coupling. Biomaterials 24, 4529-4537. (Pubitemid 36960147)
17. Gut, J. and Nelson, R. G. (1999). Cryptosporidium parvum: syncronized excystation in vitro and evaluation of sporozoite infectivity with a new Lectin-Based Assay. Journal of Eukaryotic Microbiology 46, 56S-57S. (Pubitemid 29471754)
18. Harush-Frenkel, O., Altschuler, Y. and Benita, S. (2008). Nanoparticlecell interactions: drug delivery implications. Critical Reviews in Therapeutics Drug Carrier Systems 25, 485-544.
19. Hommer, V., Eichholz, J. and Petry, F. (2003). Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. Journal of Antimicrobial Chemotherapy 52, 359-364. (Pubitemid 37120712)
20. Huang, X., Chestang, B. L. and Brazel, C. S. (2002). Minimization of initial burst in poly(vinyl alcohol) hydrogels by surface extraction and surface-preferential crosslinking. International Journal of Pharmaceutics 248, 183-192. (Pubitemid 35341422)
21. Hunter, P. R., Hughes, S., Woodhouse, S., Raj, N., Syed, Q., Chalmers, R. M., Verlander, N. Q. and Goodacre, J. (2004). Health sequelae of human cryptosporidiosis in immunocompetent patients. Clinical Infectious Diseases 39, 504-510. (Pubitemid 39120925)
22. Huwlyer, J., Wu, D. and Pardridge,W. M. (1996). Brain drug delivery of small molecules using immunoliposomes. Proceedings of the National Academy of Sciences, USA 93, 14164-14169. (Pubitemid 26424263)
23. Ives, N. J., Gazzard, B. G. and Easterbrook, P. J. (2001). The changing pattern of AIDS-defining illness with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. Journal of Infection 42, 134-139. (Pubitemid 32631815)
24. Jancis, B., Medenica, M., Ivanovic, D. and Malenovic, A. (2005). Evaluation of a liquid chromatographic method for analysis of Indinavir and degradation products arising from hydrolysis of its amide bond. Chromatographia 62, 233-238. (Pubitemid 41291580)
25. Jao, J. and Wyatt, C. M. (2010). Antiretroviral medications: adverse effects on the kidney. Advances in Chronic Kidney Disease 17, 72-82.
26. Mele, R., Gómez-Morales, M. A., Tosini, F. and Pozio, E. (2003). Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. International Journal for Parasitology 33, 757-764. (Pubitemid 36695027)
27. Miao, Y. M., Awad-El-Kariem, F. M., Franzen, C., Ellis, D. S., Müller, A., Counihan, H. M., Hayes, P. J. and Gazzard, B. G. (2000). Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome 25, 124-129.
28. Mor, S. M. and Tzipori, S. (2008). Cryptosporidiosis in children in Sub-Saharan Africa: a lingering challenge. Clinical Infectious Diseases 47, 915-921.
29. Motta, I., Gissot, M., Kanellopoulos, J. M. and Ojcius, D. M. (2002). Absence of weight loss during Cryptosporidium infection in susceptible mice deficient in Fas-mediated apoptosis. Microbes and Infection 4, 821-827. (Pubitemid 35247445)
30. Nobs, L., Buchegger, F., Gurny, R. and Allemann, E. (2004). Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting. European Journal of Pharmaceutics and Biopharmaceutics 58, 483-490. (Pubitemid 39297095)
31. Nobs, L., Buchegger, F., Gurny, R. and Allemann, E. (2003). Surface modification of poly-lactide acid nanoparticles by covalent attachment of thiol groups by means of three methods. International Journal of Pharmaceutics 250, 327-337. (Pubitemid 36084357)
32. Pereira de Oliveira, M., Garcion, E., Venisse, N., Benoit, J. P., Couet, W. and Olivier, J. C. (2005). Tissue distribution of Indinavir administered as solid lipid nanocapsule formulation in mdr1a(+/+) and mdr1a(?/?) CF-1 mice. Pharmaceutical Research 22, 1898-1905. (Pubitemid 41504343)
33. Plutzer, J. and Karanis, P. (2009). Genetic polymorphism in Cryptosporidium species: an update. Veterinary Parasitology 165, 187-199.
34. Pozio, E. and Gómez-Morales, M. A. (2005). The impact of HIV-protease inhibitors on opportunistic parasites. Trends in Parasitology 21, 58-63. (Pubitemid 40138876)
35. Rafati, H., Coombes, A. G. A., Adler, A., Holland, J. and Davis, S. S. (1997). Protein-loaded poly (DL-lactide-co-glycolide) microparticles for oral administration: formulation, structural and release characteristics. Journal of Controlled Release 43, 89-102. (Pubitemid 26393612)
36. Ranucci, L., Muller, H. M., La Rosa, G., Reckman, I., Gomez Morales, M. A., Spano, F., Pozio, E. and Crisanti, A. (1993). Characterization and immunolocalization of a Cryptosporidium parvum protein containing repeated amino acids motifs. Infection and Immunity 61, 2347-2356. (Pubitemid 23159221)
37. Rossi, P., Pozio, E., Besse, M. G., Gómez-Morales, M. A. and La Rosa, G. (1990). Experimental cryptosporidiosis in hamsters. Journal of Clinical Microbiology 28, 356-357. (Pubitemid 20050951)
38. Rossignol, J. F. (2010). Cryptosporidium and Giardia: Treatment options and prospects for new drugs. Experimental Parasitolotogy 184, 103-106.
39. Sah, H. K., Toddywala, R. and Chien, Y.W. (1994). The influence of biodegradable microcapsule formulations on the controlled release of a protein. Journal of Controlled Release 30, 201-211. (Pubitemid 24216834)
40. Sanvinvens, N. and Pilar, M. M. (2008). Multifunctional nanoparticles -properties and prospects for their use in human medicine. Trends in Biotechnology 26, 425-433.
41. Slifko, T. R., Hoffman, D. E. and Rose, J. B. (1999). A most probable number assay for enumeration of infectious Cryptosporidium parvum oocysts. Applied and Enviromental Microbiology 65, 3936-3941.
42. Torchilin, V. P. (2006). Multifunctional nanocarriers. Advanced Drug Delivery Reviews 58, 1532-1555. (Pubitemid 44822608)
43. Tosi, G., Costantino, L., Ruozi, B., Forni, F. and Vandelli, M. A. (2008). Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opinion in Drug Delivery 5, 155-174. (Pubitemid 351308309)
44. Uchida, K., Yagi, A., Oda, Y. and Goto, S. (1996). Microencapsulation of ovalbumin in poly(lactide-co-glycolide) by and oil-in-oil (o/o) solvent evaporation method. Journal of Microencapsulation 13, 509-518. (Pubitemid 26283804)
45. Upton, S. J., Tilley, M. and Brillhart, D. B. (1995). Effect of select medium supplements on in vitro development of Cryptosporidium parvum in HCT-8 cells. Journal of Clinical Microbiology 33, 371-375.
46. Violari, A., Cotton, M. F., Gibb, D. M., Babiker, A. G., Steyn, J., Madhi, S. A., Jean-Philippe, P., McIntyre, J. A. and CHER Study Team. (2008). Early antiretroviral therapy and mortality among HIV-infected infants. The New England Journal of Medicine 20, 2233-2244.
47. Wang, A. Z., Gu, F., Zhang, L., Chang, J. M., Radovic-Moreno, A., Shaikh, M. R. and Farokhzad, O. C. (2008). Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opinion on Biological Therapy 8, 1063-1070.
48. Xu, Z., Pilch, D. S., Srinivasan, A. R., Olson, W. K., Geacintov, N. E. and Breslauer, K. J. (1997). Modulation of nucleic acid structure by ligand binding induction of a DNA.RNA.DNA hybrid triplex by DAPI intercalation. Bioorganic and Medical Chemistry 5, 1137-1147. (Pubitemid 27264841)
49. Zardi, E. M., Picardi, A. and Afeltra, A. (2005). Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy 51, 193-196.